Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;8(2):94-103.
doi: 10.1007/s11904-011-0078-4.

Preexposure prophylaxis for HIV prevention

Theodoros Kelesidis  1 , Raphael J Landovitz
Affiliations
Review

Preexposure prophylaxis for HIV prevention

Theodoros Kelesidis et al. Curr HIV/AIDS Rep. 2011 Jun.

Abstract

Reducing the incidence of HIV remains one of our greatest public health challenges. However, there is growing optimism that preexposure prophylaxis (PrEP) could have a major impact on preventing incident HIV infection. Recently presented data on the use of oral PrEP in men who have sex with men (MSM) have provided proof-of-principle for this strategy. Additional clinical trials are evaluating whether PrEP provides similar protection to risk groups other than MSM, such as heterosexual persons and injection drug users. Still unanswered questions include optimal dosing strategies, long-term safety, maximizing adherence and minimizing costs, addressing drug resistance in the face of PrEP failure, optimizing access, and assessing effects on risk behavior. Future implementation will be guided by the results of clinical trials in progress. This article provides a review of the data on the potential strengths and limitations of PrEP as an HIV prevention strategy, identifies challenges to implementation of this approach, and outlines knowledge gaps.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009;361(18):1768–75. - PubMed

    1. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–56. A randomized trial of 2784 young men age 18 to 24 in Kisumu, Kenya demonstrated a 53% reduction in HIV acquisition among men who were randomized to the circumcision intervention compared with men randomized to the nonsurgical arm.

    1. Abdool KQ, Karim SS Abdool, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. A randomized trial of 889 women in South Africa demonstrated a 39% reduction in HIV acquisition among women who were randomized to a coitally-dependent regimen of 1% tenofovir gel compared to women randomized to a placebo arm, both when combined with intensive testing and risk reduction counseling.

    1. Vermund SH, Van DL. HIV prevention in women: next steps. Science. 2011;331(6015):284. - PubMed
    1. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS. 2010;5(5):428–34. - PMC - PubMed

Publication types

Substances